RxDoctor Payments Data

Jami Newman, MD

Family Medicine · Lansing, MINPI 1942368436

Payments from drug & device makers

$1,108in general payments, 2019–2025

Across 58 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$325
  • Novo Nordisk$135
  • Abbott$125
  • Boehringer Ingelheim$101
  • Pfizer$76
  • Exact Sciences$70
  • plus $276 from 11 others

What the payments were for

  • Food & beverage$1,108100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,108 in reported general payments places this provider in the 70th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$17,106
Medicare patients
56
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$96,233
TrulicityDulaglutide25$54,216
JardianceEmpagliflozin38$40,718
EliquisApixaban29$31,041
XareltoRivaroxaban16$24,842
Breo ElliptaFluticasone/Vilanterol24$19,330
FarxigaDapagliflozin Propanediol23$13,751
Rosuvastatin Calcium138$4,388
Levothyroxine Sodium190$3,005
Estradiol19$2,464
Duloxetine Hcl35$2,327
Albuterol Sulfate HfaAlbuterol Sulfate37$2,096
Tadalafil13$1,910
Celecoxib41$1,791
Atorvastatin Calcium151$1,724

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$325$54,21625 claims
Boehringer IngelheimJardiance$101$40,71838 claims
PfizerEliquis$76$31,04129 claims
Johnson & JohnsonXarelto$13$24,84216 claims
GSKBreo Ellipta$54$19,33024 claims
AstraZenecaFarxiga$30$13,75123 claims
AbbVieSynthroid$18$96422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →